Pediatric Pertussis in Ambulatory Settings

Since 2002, Whooping cough surveillance in pediatric private practice has been set up in France. The results of the first years, 2002-2006, have confirmed the effectiveness of the Pertussis whole-cell (Pw) vaccine and in particular the duration of protection of 9/10 years. After evaluating cases in children vaccinated with Pw vaccines, the study aims today to analyze cases in children vaccinated with Pertussis acellular (Pa) vaccines used since 2002/2003 and to assess, on an outpatient basis, the impact of new vaccine recommendations in France (in 2013, introduction of a 2 + 1 schedule - 8 weeks, 4 months and a 11-month recall - and a 6-year recall, and in 2014, update in the recommendations of exams to be prescribed based on the child's age and vaccination status).

NCT Number	NCT04807712
Lead Sponsor	Association Clinique Thérapeutique Infantile du val de Marne Collaborators: GlaxoSmithKline, Sanofi, Merck Sharp & Dohme LLC
Conditions	Pertussis/Whooping Cough, Children, Only, Ambulatory
Enrollment	898 participants
Start Date	2001-05-30
Primary Completion	2030-01-01 (estimated)
Study Completion	2030-01-01 (estimated)
Updated on ClinicalTrials.gov	2024-02-08